Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oprozomib Food Effect and DDI Study in Advanced Malignancies
NCT02244112Phase 1Terminated
- Sponsor
- Amgen
- Start
- Aug 2014
- Primary completion
- May 2015
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of oprozomib in cancer (5 arms), sponsored by Amgen. Primary endpoints: Maximum Plasma Concentration at 2 weeks, Area Under the Curve at 2 weeks and 5 more. Started Aug 2014; status: terminated.
02
Drugs
oprozomib
03
Conditions
cancer
Beyond the preview
Go deeper on NCT02244112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02244112.